JP2008507579A5 - - Google Patents

Download PDF

Info

Publication number
JP2008507579A5
JP2008507579A5 JP2007523605A JP2007523605A JP2008507579A5 JP 2008507579 A5 JP2008507579 A5 JP 2008507579A5 JP 2007523605 A JP2007523605 A JP 2007523605A JP 2007523605 A JP2007523605 A JP 2007523605A JP 2008507579 A5 JP2008507579 A5 JP 2008507579A5
Authority
JP
Japan
Prior art keywords
methyl
ethyl
pyrrolidin
oxazol
oxazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007523605A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008507579A (ja
JP4982367B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/024883 external-priority patent/WO2006019833A1/en
Publication of JP2008507579A publication Critical patent/JP2008507579A/ja
Publication of JP2008507579A5 publication Critical patent/JP2008507579A5/ja
Application granted granted Critical
Publication of JP4982367B2 publication Critical patent/JP4982367B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007523605A 2004-07-26 2005-07-14 ヒスタミンh3受容体薬剤としてのオキサゾール誘導体、製造及び治療的使用 Expired - Fee Related JP4982367B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59119104P 2004-07-26 2004-07-26
US60/591,191 2004-07-26
PCT/US2005/024883 WO2006019833A1 (en) 2004-07-26 2005-07-14 Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses

Publications (3)

Publication Number Publication Date
JP2008507579A JP2008507579A (ja) 2008-03-13
JP2008507579A5 true JP2008507579A5 (enExample) 2012-03-08
JP4982367B2 JP4982367B2 (ja) 2012-07-25

Family

ID=35134220

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007523605A Expired - Fee Related JP4982367B2 (ja) 2004-07-26 2005-07-14 ヒスタミンh3受容体薬剤としてのオキサゾール誘導体、製造及び治療的使用

Country Status (17)

Country Link
US (1) US7666871B2 (enExample)
EP (1) EP1786790B1 (enExample)
JP (1) JP4982367B2 (enExample)
CN (1) CN1989115B (enExample)
AT (1) ATE432926T1 (enExample)
AU (1) AU2005275183B2 (enExample)
BR (1) BRPI0513777A (enExample)
CA (1) CA2575081C (enExample)
CY (1) CY1109493T1 (enExample)
DE (1) DE602005014786D1 (enExample)
DK (1) DK1786790T3 (enExample)
ES (1) ES2325865T3 (enExample)
MX (1) MX2007001029A (enExample)
PL (1) PL1786790T3 (enExample)
PT (1) PT1786790E (enExample)
SI (1) SI1786790T1 (enExample)
WO (1) WO2006019833A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008301B2 (en) * 2004-04-01 2011-08-30 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
EP1848428A4 (en) 2005-02-18 2012-04-18 Neurogen Corp THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGS
EP1866293A1 (en) * 2005-03-31 2007-12-19 UCB Pharma, S.A. Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses
US8637559B2 (en) 2005-11-15 2014-01-28 Otsuka Pharmaceutical Co., Ltd. Oxazole compound and pharmaceutical composition
CA2645731A1 (en) 2006-03-15 2007-09-27 Wyeth N-substituted-azacyclylamines as histamine-3 antagonists
CA2649913A1 (en) 2006-05-19 2007-11-29 Wyeth N-benzoyl- and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
BRPI0711655A2 (pt) * 2006-05-19 2011-11-29 Basf Se composto, processo para preparar compostos, composição, processo para preparar composições, proceeso para combater vegetação indesejada, e, uso do composto
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PE20081152A1 (es) 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
JP2010533725A (ja) 2007-07-16 2010-10-28 ワイス・エルエルシー ヒスタミン‐3(h3)受容体としてのアミノアルキルアゾール化合物
WO2009126782A1 (en) * 2008-04-11 2009-10-15 High Point Pharmaceuticals, Llc Histamine h3 receptor ligands
US8383829B2 (en) * 2008-04-15 2013-02-26 Konica Minolta Holdings, Inc. Electrochromic compound, electrode, and display element
SA110310332B1 (ar) 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
SG186275A1 (en) 2010-07-06 2013-01-30 Astrazeneca Ab Therapeutic agents 976
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
SG11201505631PA (en) 2013-01-23 2015-08-28 Astrazeneca Ab Chemical compounds
WO2016097071A1 (en) * 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Estrogen receptor modulators and uses thereof
PE20180506A1 (es) 2015-06-03 2018-03-09 Bristol Myers Squibb Co Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
PT3319959T (pt) 2015-07-06 2021-12-06 Alkermes Inc Inibidores hetero-halo de histona desacetilase
MX394242B (es) 2017-01-11 2025-03-24 Rodin Therapeutics Inc Inhibidores biciclicos de histona desacetilasa
MX2020001484A (es) 2017-08-07 2020-08-20 Rodin Therapeutics Inc Inhibidores bicíclicos de la histona desacetilasa.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3819037A1 (de) * 1988-06-04 1989-12-14 Hoechst Ag 2,4-disubstituierte oxazol-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als therapiemittel gegen krankheiten, die durch rhinoviren verursacht werden
AU674613B2 (en) * 1993-09-28 1997-01-02 Otsuka Pharmaceutical Co., Ltd. Quinoxaline derivative as antidiabetic agent
WO2000064884A1 (en) * 1999-04-26 2000-11-02 Novo Nordisk A/S Piperidyl-imidazole derivatives, their preparations and therapeutic uses
CA2441080A1 (en) 2001-03-23 2002-10-03 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
IL162834A0 (en) 2002-02-01 2005-11-20 Novo Nordisk As Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes
US7332508B2 (en) * 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
US7259262B2 (en) * 2003-10-24 2007-08-21 Hoffmann-La Roche Inc. Arylazole derivatives, their manufacture and use as pharmaceutical agents

Similar Documents

Publication Publication Date Title
JP2008507579A5 (enExample)
CA2575081A1 (en) Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses
JP2007510713A5 (enExample)
JP2010539152A5 (enExample)
RU2352568C9 (ru) [1,2,4]оксадиазолы (варианты), способ их получения, фармацевтическая композиция и способ ингибирования активации метаботропных глютаматных рецепторов-5
ES2617221T3 (es) Derivados de 3-(2-aril-cicloalquenilmetil)-oxazolidin-2-ona como inhibidores de la proteína de transferencia de ésteres de colesterol (CETP)
RU2018138707A (ru) Замещенные гетероарилом пиридины и способы применения
JP2006502134A5 (enExample)
JP2015533157A5 (enExample)
JP2008503497A5 (enExample)
JP2005529077A5 (enExample)
JP2007508346A5 (enExample)
JP2018535999A5 (enExample)
JP2015509510A5 (enExample)
JP2005500986A5 (enExample)
HRP20211960T1 (hr) Alosterični modulatori nikotinskih acetilcolinskih receptora
JP2015517580A5 (enExample)
JP2010513397A5 (enExample)
JP2010502615A5 (enExample)
JP2004537554A5 (enExample)
RU2010137300A (ru) Модуляторы бета-амилоида
RU2008126398A (ru) Производные гетероарилзамещенного пиперидина в качестве ингибиторов печеночной карнитин пальмитоилтрансферазы (l-cpti)
JP2014513120A5 (enExample)
JP2007523208A5 (enExample)
RU2018143324A (ru) Применение 1H-пиразоло[4,3-b]пиридинов в качестве ингибиторов PDE1